Craft

Evotec

Stock Price

€10.5

2024-05-15

Market Capitalization

€1.9 B

2024-05-15

Revenue

€781.4 M

FY, 2023

Evotec Summary

Company Summary

Overview
Evotec is a drug discovery alliance and development partnership company. It provides pharmaceutical and biotechnology companies, academics, patient advocacy groups, and venture capital firms with drug discovery solutions in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of innovative drug candidates, and consulting arrangements. The company specializes in the areas of neuroscience, diabetes, complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases, and fibrosis.
Type
Public
Status
Active
Founded
1993
HQ
Hamburg, DE | view all locations
Website
https://www.evotec.com/
Cybersecurity rating
ESG rating
50-59 out of 100|View all ESG data
Sectors

Key People

  • Craig Johnstone

    Craig Johnstone, Chief Operating Officer

  • Cord Dohrmann

    Cord Dohrmann, Chief Scientific Officer

  • Volker Braun

    Volker Braun, SVP, Head of Global Investor Relations & ESG

  • Matthias Evers

    Matthias Evers, Chief Business Officer

Operating MetricsView all

Products

130
13.3%

FY, 2021

New Customers

337
7.0%

FY, 2021

Customers

842
1.6%

FY, 2021

LocationsView all

16 locations detected

  • Hamburg, HH HQ

    Germany

    Essener Bogen 7

  • Branford, CT

    United States

    33 Business Park Drive #6

  • Princeton, NJ

    United States

    303B College Road East

  • Redmond, WA

    United States

    22857 NE Marketplace Drive

  • Seattle, WA

    United States

    401 Terry Ave N

  • Orth an der Donau, Niederösterreich

    Austria

    Uferstraße 15

and 10 others

Evotec Financials

Summary Financials

Revenue (FY, 2023)
€781.4M
Gross profit (FY, 2023)
€281.9M
Net income (FY, 2023)
(€83.9M)
Cash (FY, 2023)
€510.9M
EBIT (FY, 2023)
(€68.3M)
Enterprise value
$2.0B

Footer menu